Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

$250,000 top award goes to Neel Moudgal in the nation's oldest and most prestigious science and math competition for high school seniors TARRYTOWN, N.Y. and WASHINGTON, March 14, 2023 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.  and Society for Science  (the Society) announced that Neel Moudgal, 17, of Saline, Mich.

Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Oppenheimer 33rd Annual Healthcare Conference March 13, 2023 9:20 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Neil Stahl - Executive Vice President, Research and Development Jamie Orengo - Vice President, Allergy and Immunity Research Conference Call Participants Hartaj Singh - Oppenheimer Hartaj Singh Great. For joining us, I always have to remember to give that pause.

Regeneron Pharmaceuticals, Inc. (REGN) Oppenheimer 33rd Annual Healthcare Conference

Eylea, the company's top-selling blockbuster, isn't going away soon.

Regeneron Borrows From Big Pharma Playbook

Beam Therapeutics

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Novartis

Verve Therapeutics

Vertex Pharmaceuticals

These CRISPR stocks could be big winners for patient investors.

Investing in Top CRISPR Companies

Sanofi

Dupixent ® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines

Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Cowen 43rd Annual Health Care Conference March 6, 2023 12:50 PM ET Company Participants Marion McCourt - EVP of Commercial Ryan Crowe - Vice President & Head of IR Conference Call Participants Tyler Van Buren - Cowen Tyler Van Buren Good afternoon, everyone. I'm Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.

Regeneron Pharmaceuticals, Inc. (REGN) Cowen 43rd Annual Health Care Conference (Transcript)

Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial

Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica

Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy alone Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy alone

Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)

Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA.

Regeneron (REGN) Rare Disease Drug Gets FDA's Priority Review

If approved, pozelimab would be the first and only treatment for those living with CHAPLE

Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review

AbbVie

Alvotech SA

Amgen

Bristol-Myers

Coherus BioSciences

Cigna

CVS Health

Fresenius Medical Care

GlaxoSmithKline

Johnson & Johnson

Merck

Novo Nordisk

Organon & Co

Pfizer

Roche Holding AG

Teva Pharmaceutical

Viatris

It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.

Competition Coming For AbbVie's Blockbuster Humira

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) SVB Securities Global Biopharma Conference February 14, 2023 9:20 AM ET Company Participants Ryan Crowe - VP, IR Izzy Lowy - SVP of Clinical Development for Oncology Andres Sirulnik - SVP, Translational & Clinical Sciences, Hematology Conference Call Participants David Risinger - SVB Securities David Risinger So good morning, everybody, and thank you for joining our session with Regeneron. My name is Dave Risinger.

Regeneron Pharmaceuticals, Inc. (REGN) SVB Securities Global Biopharma Conference (Transcript)

Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).

Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants

ROP is a leading cause of childhood blindness worldwide

EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA

Chimerix

Genfit - ADR

Harmony Biosciences Holdings

iTeos Therapeutics, Inc.

Selecta Biosciences

While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy.

The 7 Best Biotech Stocks to Buy for February 2023

Exact Sciences

Gilead Sciences

Immunocore Holdings

Eli Lilly

Moderna

The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Moderna Inc. (NASDAQ: MRNA), among others.

Is Biotech Immunocore About To Make A 25% Price Move?

Analog Devices

Regeneron and Analog Devices hit new highs and break out. REGN had strong fourth quarter earnings.

Drug, Chip Stocks Hit 52-Week Highs As One Breaks Out Of Bullish Chart Pattern

While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics

Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.

Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q4 2022 Earnings Conference Call February 3, 2023 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - Co-Founder, President and Chief Executive Officer George Yancopoulos - Co-Founder, President and Chief Scientific Officer Marion McCourt - Executive Vice President and Head, Commercial Bob Landry - Executive Vice President and Chief Financial Officer Conference Call Participants Tyler Van Buren - Cowen Matthew Harrison - Morgan Stanley Carter Gould - Barclays Brian Abrams - RBC Capital Markets Evan Seigerman - BMO Capital Markets Salveen Richter - Goldman Sachs Mohit Bansal - Wells Fargo Colin Bristow - UBS Chris Raymond - Piper Sandler Chris Schott - JPMorgan Robyn Karnauskas - Truist Operator Welcome to the Regeneron Pharmaceuticals' Fourth Quarter 2022 Earnings Conference Call. My name is Shannon and I will be your operator for today's call.

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2022 Earnings Call Transcript

Regeneron Pharma beat quarterly forecasts Friday, but its partner Sanofi posted a mixed report. Regeneron stock rose as SNY stock toppled.

Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples

Regeneron (REGN) delivered earnings and revenue surprises of 29.75% and 7.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates

Shares of Regeneron Pharmaceuticals Inc. REGN, -0.90% rallied 1.9% toward a two-month high in premarket trading Friday, after the biotechnology company reported fourth-quarter profit and revenue that fell, as sales of its COVID-19 treatment dropped, but beat expectations by wide margins. Net income fell to $1.20 billion, or $10.50 a share, from $2.23 billion, or $19.69 a share, in the year-ago period.

Regeneron stock rallies after profit and revenue beat expectations by wide margins

TARRYTOWN, N.Y., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2022 and provided a business update.

News for Regeneron Pharmaceuticals Stock (REGN)